文献速递头颈部肿瘤放疗中枢神经肿瘤放疗姑息放疗与转移瘤

接受放疗患者的缺铁情况:患病率与临床特征

Iron deficiency in patients undergoing radiotherapy: Prevalence and clinical characteristics.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-01-18

这项回顾性研究纳入156例以头颈部癌、脑恶性肿瘤或转移性疾病为主、接受放化疗的患者,评估放化疗对铁代谢的影响。结果显示治疗前贫血患病率为53.8%、缺铁为44.2%,放疗结束时贫血升至74.1%;口服铁补充作为营养补充未能影响转铁蛋白饱和度轨迹。

要点

  • 放化疗患者治疗前贫血患病率53.8%,放疗结束时升至74.1%。
  • 基线缺铁患病率44.2%,基线缺铁与新辅助全身治疗相关。
  • 口服铁补充作为营养补充未影响转铁蛋白饱和度变化轨迹。

核心结论

  • 接受放疗的患者贫血患病率极高,缺铁是主要原因之一。
  • 口服铁补充可能不足以治疗放疗患者的缺铁,需更深入理解铁平衡并优化补铁策略。

研究设计与样本

  • 回顾性研究,纳入156例接受放化疗的癌症患者,主要为头颈部癌、脑恶性肿瘤或转移性疾病。
  • 在放化疗前、中、后多个时间点检测铁、铁蛋白、转铁蛋白等血液参数。

主要发现

  • 贫血患病率治疗前为53.8%,放疗结束时升至74.1%。
  • 基线时44.2%的患者存在缺铁。
  • 基线缺铁与全身治疗相关(16.5%的患者接受新辅助治疗)。
  • 治疗结束时低转铁蛋白饱和度与酒精滥用相关。
  • 放化疗期间患者转铁蛋白饱和度呈现升高、降低和不变三种变化轨迹,且该轨迹与口服铁补充作为营养补充无关。

关键数值与推荐

  • 贫血定义:男性血红蛋白水平<13 mg/L,女性<12 mg/L。
  • 缺铁定义:转铁蛋白饱和度(TSAT)低于20%。

临床怎么用

  • 放疗患者应关注贫血与缺铁的高患病率,并在治疗前及治疗中评估铁代谢指标。
  • 口服铁补充作为营养补充可能不足以纠正放疗患者的缺铁,需考虑更有效的补铁策略。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Anemia in patients undergoing radio-chemotherapy (RCTx) is often driven by iron deficiency and can impact quality of life and therapy outcomes. This study aimed to evaluate how RCTx affects iron metabolism and identify additional influencing factors. METHODS: We conducted a retrospective study on 156 patients with cancer undergoing RCTx, primarily with head and neck cancer, brain malignancies, or metastatic disease. Anemia was defined as a HB level < 13 mg/L in men and < 12 mg/L in women. Iron deficiency was defined as a transferrin saturation (TSAT) below 20 %. Further blood parameters, including iron, ferritin, and transferrin, were assessed at multiple timepoints before, during, and after RCTx. RESULTS: Prevalence of anemia was 53.8% prior to treatment and increased up to 74.1% at the end of radiotherapy. At baseline, 44.2% of patients were iron deficient. Iron deficiency at baseline was associated with systemic treatment (16.5% of patients with neoadjuvant treatment), while low TSAT at end of treatment was associated with alcohol abuse. During the course of the RCTx patients with divergent changes of TSAT levels were identified (increase, decrease and no change of TSAT). Trajectory of TSAT levels was independent of oral iron substitution as nutritional supplement. CONCLUSION: Patients undergoing radiotherapy show an exceptionally high prevalence for anemia, with iron deficiency being one of the main causes. Our study suggests that oral iron substitution may not be sufficient to treat iron deficiency in patients undergoing radiotherapy, underlining the need to enhance our understanding of iron balance and how to best target deficiencies in these patients.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Schumacher S, Fabian F, Lehmann P, et al. Iron deficiency in patients undergoing radiotherapy: Prevalence and clinical characteristics. Clin Transl Radiat Oncol. 2026. PMID: 41631034. doi:10.1016/j.ctro.2026.101111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。